Business Context and Reporting Period
This Form 8-K reports the results of the Annual Meeting of Stockholders held by Compass Therapeutics, Inc. on June 10, 2026. The filing details the voting outcomes for four proposals submitted to security holders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
The following matters were submitted to a vote of stockholders:
- Proposal 1: Election of Directors. Stockholders elected two Class III nominees to serve until the 2029 Annual Meeting:
- Thomas J. Schuetz, M.D., Ph.D.: 102,984,184 votes For; 18,837,499 votes Withheld.
- Richard S. Lindahl, M.B.A.: 103,453,540 votes For; 18,368,143 votes Withheld.
- Proposal 2: Ratification of Auditors. Stockholders ratified the appointment of CohnReznick, LLP as the independent registered public accounting firm for the year ending December 31, 2026.
- For: 137,896,097
- Against: 181,037
- Withheld: 5,064,867
- Proposal 3: Advisory Vote on Executive Compensation. Stockholders approved the compensation of Named Executive Officers on a non-binding basis.
- For: 117,963,684
- Against: 1,796,022
- Abstain: 2,061,977
- Proposal 4: Frequency of Future Advisory Votes. Stockholders voted to hold future advisory votes on executive compensation annually.
- Every Year: 118,289,260
- Every Two Years: 811,275
- Every Three Years: 1,491,631
Guidance, Outlook, and Risks
The filing does not contain financial guidance, operational outlook, or specific risk factors. The Board of Directors has determined to provide for an annual stockholder advisory vote on executive compensation based on the meeting results, though they reserve the right to determine a different frequency in the future if deemed in the best interests of stockholders.
Investor Verification Checklist
- Verify the definitive proxy statement (Form DEF 14A) filed on April 29, 2026, for detailed descriptions of the proposals.
- Confirm the tenure of the newly elected Class III directors (Thomas J. Schuetz and Richard S. Lindahl) through the 2029 Annual Meeting.
- Review the engagement letter with CohnReznick, LLP for the 2026 fiscal year audit scope and fees.
- Monitor future Board determinations regarding the frequency of executive compensation advisory votes.